It is suggested that gefitinib might reverse tumor resistance to SN-38 mediated by ABCG2 by blocking the drug efflux function and might be beneficial in humans to regulate the oral bioavailability of poorly absorbed drugs such as irinotecan [85]. This evidence concerns the gene ABCG2 and neoplasm.